CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022
|出版日期||內容資訊||英文 86 Pages
|CNV-1014802(神經病變性疼痛治療藥):市場預測與分析 CNV-1014802 (Neuropathic Pain) - Forecast and Market Analysis to 2022|
|出版日期: 2014年04月30日||內容資訊: 英文 86 Pages||
CNV-1014802是Convergence Pharmaceuticals針對壓迫性神經病變(腰薦神經叢病變，三叉神經痛(TN))等相關疼痛所開發的新治療藥。這個藥劑也與CNV-2197944相同，是在GlaxoSmithKline(GSK)在取得Convergence Pharmaceuticals18%的股權時，作為條件由GSK方簽下收購契約。CNV-1014802是一種能阻礙傳達痛覺的Nav1.7鈉流通管道的小分子，其實驗模組顯示出它可阻礙高頻率、自然發生的神經元放電（三叉神經痛(TN)常見的特徵）。
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability. New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
CNV-1014802 is a novel therapy being developed by Convergence Pharmaceuticals for the treatment of pain associated with entrapment neuropathies, such as lumbosacral radiculopathy and TN. Like CNV-2197944, CNV-1014802 was acquired from GSK in 2010 as part of an agreement in which the company acquired an 18% minority equity stake in Convergence Pharmaceuticals. CNV-1014802 is a small molecule that blocks the Nav1.7 sodium channels, which are involved in transmitting pain signals. It was demonstrated in experimental models to block the high frequency and spontaneous neuronal firing that is often characteristic of TN.